タイサブリ（ナタリズマブ）の世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

タイサブリ（ナタリズマブ）の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8％で36億米ドルに成長します。予測期間の成長は、自己免疫疾患の有病率の増加、多発性硬化症やクローン病における効果的な治療に対する需要の高まり、バイオシミラーの進歩、十分な治療を受けていない地域における患者アクセスの拡大、他の自己免疫疾患での使用を裏付ける進行中の臨床研究に起因しています。予測期間における世界の動向としては、バイオシミラーの採用拡大、多発性硬化症以外の治療用途の拡大、個別化医療への注目の高まり、世界の流通のためのパートナーシップの拡大、アフォーダビリティイニシアチブを通じた患者アクセスの強化、免疫調整療法の継続的な進歩などが挙げられます。

タイサブリ（ナタリズマブ）市場の成長は、自己免疫疾患の有病率の上昇に大きく影響されています。多発性硬化症やクローン病などの自己免疫疾患は、免疫系が体内組織を攻撃することで発症し、炎症や長期的な損傷を引き起こします。このような自己免疫疾患の増加は、遺伝的要因、環境の影響、認知度や診断の向上と関連しており、より多くの症例が特定されるようになっています。2024年3月、全米保健協議会は、自己免疫疾患が約5,000万人のアメリカ人に影響を及ぼし、症例数は毎年3～12％増加していると報告しました。世界的にみても、多発性硬化症の症例数は2022年には前の10年と比較して30％増加しています。その結果、特定の免疫細胞を標的として炎症を予防するタイサブリは、これらの疾患に対する必須の治療となりつつあり、市場の成長を牽引しています。

個別化医療の動向の高まりがタイサブリ市場を後押ししています。個別化医療は、患者の遺伝的体質、環境、ライフスタイルに基づいて治療を調整し、副作用を最小限に抑えながら有効性を高めるものです。タイサブリはそのような治療の一例であり、特に再発型の多発性硬化症に対する治療です。タイサブリは特定の疾患活動やリスクプロファイルを標的とし、より正確な治療効果を保証します。2023年にFDAが16の新規個別化治療を承認することは、標的治療に対する需要の高まりを浮き彫りにし、タイサブリや類似の治療法の採用をさらに後押しします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のタイサブリ（ナタリズマブ）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のタイサブリ（ナタリズマブ）市場：成長率分析
• 世界のタイサブリ（ナタリズマブ）市場の実績：規模と成長、2019～2024年
• 世界のタイサブリ（ナタリズマブ）市場の予測：規模と成長、2024～2029年、2034年
• 世界のタイサブリ（ナタリズマブ）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のタイサブリ（ナタリズマブ）市場：疾患別、実績と予測、2019～2024年、2024～2029年、2034年
• 多発性硬化症
• クローン病
• 世界のタイサブリ（ナタリズマブ）市場：患者別、実績と予測、2019～2024年、2024～2029年、2034年
• 入院患者
• 外来患者
• 世界のタイサブリ（ナタリズマブ）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のタイサブリ（ナタリズマブ）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のタイサブリ（ナタリズマブ）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• タイサブリ（ナタリズマブ）市場：競合情勢
• タイサブリ（ナタリズマブ）市場：企業プロファイル
  • Biogen Idec Inc.
  • Sandoz International GmbH
  • Polpharma Biologics

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• タイサブリ（ナタリズマブ）市場、2029年：新たな機会を提供する国
• タイサブリ（ナタリズマブ）市場、2029年：新たな機会を提供するセグメント
• タイサブリ（ナタリズマブ）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Tysabri (natalizumab) is a monoclonal antibody used to treat relapsing multiple sclerosis (MS) and Crohn's disease by reducing inflammation and nerve damage. It helps decrease the frequency of relapses and slows the progression of physical disability in adults with relapsing forms of MS, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for tysabri (natalizumab) are multiple sclerosis and Crohn's disease. Multiple sclerosis is a condition that causes the breakdown of the protective covering of nerves. Tysabri is used in various patient settings, including inpatient and outpatient, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The tysabri (natalizumab) market research report is one of a series of new reports from The Business Research Company that provides tysabri (natalizumab) market statistics, including tysabri (natalizumab) industry global market size, regional shares, competitors with a tysabri (natalizumab) market share, detailed tysabri(natalizumab) market segments, market trends, and opportunities, and any further data you may need to thrive in the tysabri(natalizumab) industry. This tysabri(natalizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tysabri (natalizumab) market size is expected to see strong growth in the next few years. It will grow to $3,600 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing prevalence of autoimmune disorders, growing demand for effective treatments in multiple sclerosis and Crohn's disease, advancements in biosimilars, expanding patient access in underserved regions, and ongoing clinical research supporting its use in other autoimmune conditions. Major trends in the forecast period include rising adoption of biosimilars, the expansion of their therapeutic applications beyond multiple sclerosis, increased focus on personalized medicine, growing partnerships for global distribution, enhanced patient access through affordability initiatives, and continued advancements in immune-modulating therapies.

The growth of the tysabri (natalizumab) market is being significantly influenced by the rise in the prevalence of autoimmune disorders. Autoimmune conditions, such as multiple sclerosis and Crohn's disease, occur when the immune system attacks the body's own tissues, causing inflammation and long-term damage. This increase in autoimmune diseases is linked to genetic factors, environmental influences, and improved awareness and diagnosis, leading to more cases being identified. In March 2024, the National Health Council reported that autoimmune diseases affected approximately 50 million Americans, with the number of cases rising by 3-12% annually. Globally, multiple sclerosis cases grew by 30% in 2022 compared to the previous decade. As a result, Tysabri, which targets specific immune cells to prevent inflammation, is becoming an essential treatment for these conditions, driving market growth.

The rising trend of personalized medicine is propelling the tysabri market. Personalized medicine tailors treatments based on a patient's genetic makeup, environment, and lifestyle, improving efficacy while minimizing side effects. Tysabri is an example of such treatment, particularly for relapsing forms of multiple sclerosis. It targets specific disease activities and risk profiles, ensuring more precise therapeutic outcomes. The FDA's approval of 16 novel personalized therapies in 2023 highlights the growing demand for targeted treatments, further driving the adoption of Tysabri and similar therapies.

A key trend in the tysabri (natalizumab) market is the growing focus on biosimilars, which offer cost-effective alternatives to branded drugs like Tysabri. In January 2024, Sandoz launched Tyruko (natalizumab), the first biosimilar to Tysabri for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). This development not only strengthens the biosimilar portfolio but also enhances patient access to effective and affordable treatments, particularly in underserved regions. The increasing availability of biosimilars is expected to expand the market for Tysabri, improving overall disease management and patient outcomes.

Major players operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, and Polpharma Biologics.

North America was the largest region in the tysabri (natalizumab) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tysabri (natalizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tysabri (natalizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tysabri market consists of sales of monoclonal antibody therapies, infusion treatments, and immunomodulatory solutions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tysabri (natalizumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tysabri (natalizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tysabri (natalizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tysabri (natalizumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Clinical Indication: Multiple Sclerosis; Crohn's Disease
• 2) By Patient Setting: Inpatient; Outpatient
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Biogen Idec Inc.; Sandoz International GmbH; Polpharma Biologics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tysabri (natalizumab) Market Characteristics

3. Tysabri (natalizumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Tysabri (natalizumab) Market Trends And Strategies

5. Tysabri (natalizumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Tysabri (natalizumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Tysabri (natalizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Tysabri (natalizumab) Market Growth Rate Analysis
• 6.4. Global Tysabri (natalizumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Tysabri (natalizumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Tysabri (natalizumab) Total Addressable Market (TAM)

7. Global Tysabri (natalizumab) Market Pricing Analysis & Forecasts

8. Tysabri (natalizumab) Market Segmentation

• 8.1. Global Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multiple Sclerosis
• Crohn's Disease
• 8.2. Global Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inpatient
• Outpatient
• 8.3. Global Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

9. Global Tysabri (natalizumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Tysabri (natalizumab) Market Regional And Country Analysis

• 10.1. Global Tysabri (natalizumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Tysabri (natalizumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Tysabri (natalizumab) Market

• 11.1. Asia-Pacific Tysabri (natalizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Tysabri (natalizumab) Market

• 12.1. China Tysabri (natalizumab) Market Overview
• 12.2. China Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Tysabri (natalizumab) Market

• 13.1. India Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Tysabri (natalizumab) Market

• 14.1. Japan Tysabri (natalizumab) Market Overview
• 14.2. Japan Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Tysabri (natalizumab) Market

• 15.1. Australia Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Tysabri (natalizumab) Market

• 16.1. South Korea Tysabri (natalizumab) Market Overview
• 16.2. South Korea Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Tysabri (natalizumab) Market

• 17.1. Western Europe Tysabri (natalizumab) Market Overview
• 17.2. Western Europe Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Tysabri (natalizumab) Market

• 18.1. UK Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Tysabri (natalizumab) Market

• 19.1. Germany Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Tysabri (natalizumab) Market

• 20.1. France Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tysabri (natalizumab) Market

• 21.1. Eastern Europe Tysabri (natalizumab) Market Overview
• 21.2. Eastern Europe Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Tysabri (natalizumab) Market

• 22.1. North America Tysabri (natalizumab) Market Overview
• 22.2. North America Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Tysabri (natalizumab) Market

• 23.1. USA Tysabri (natalizumab) Market Overview
• 23.2. USA Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Tysabri (natalizumab) Market

• 24.1. Canada Tysabri (natalizumab) Market Overview
• 24.2. Canada Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Tysabri (natalizumab) Market

• 25.1. South America Tysabri (natalizumab) Market Overview
• 25.2. South America Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Tysabri (natalizumab) Market

• 26.1. Middle East Tysabri (natalizumab) Market Overview
• 26.2. Middle East Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Tysabri (natalizumab) Market

• 27.1. Africa Tysabri (natalizumab) Market Overview
• 27.2. Africa Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Tysabri (natalizumab) Market Competitive Landscape And Company Profiles

• 28.1. Tysabri (natalizumab) Market Competitive Landscape
• 28.2. Tysabri (natalizumab) Market Company Profiles
  • 28.2.1. Biogen Idec Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Sandoz International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.3. Polpharma Biologics Overview, Products and Services, Strategy and Financial Analysis

29. Global Tysabri (natalizumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Tysabri (natalizumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Tysabri (natalizumab) Market

32. Recent Developments In The Tysabri (natalizumab) Market

33. Tysabri (natalizumab) Market High Potential Countries, Segments and Strategies

• 33.1 Tysabri (natalizumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Tysabri (natalizumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Tysabri (natalizumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer